Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENITY study of subcutaneous efgartigimod in Sjogren’s disease-associated polyneuropathy
2026-526218-10-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Oct 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome and sensory polyneuropathy comparing Vyvgart with Placebo (2 arms). Primary endpoint: Change from baseline in mTCNS total score at the end of Part A. Planned start Oct 2026; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
Sjögren's syndromesensory polyneuropathy
Beyond the preview
Go deeper on 2026-526218-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526218-10-00.